Cover Image

Improving Regulatory Transparency for New Medical Therapies Act : report (to accompany H.R. 639).

Bibliographic Details
Corporate Author:	United States. Congress. House. Committee on Energy and Commerce (Author)
Format:	Government Document eBook
Language:	English
Published:	[Washington, D.C.] : [U.S. Government Publishing Office], [2015]-
Series:	Rept. / 114th Congress, 1st session, House of Representatives ; 114-41
Subjects:	Drugs of abuse > Law and legislation > United States. Drug approval > United States. Legislative materials.
Online Access:	https://purl.fdlp.gov/GPO/gpo56344 http://purl.fdlp.gov/GPO/gpo56344

Similar Items

Improving Regulatory Transparency for New Medical Therapies Act : report (to accompany H.R. 4299) (including cost estimate of the Congressional Budget Office).
Published: (2014)

Opioid Review Modernization Act of 2016 : report (to accompany H.R. 4976) (including cost estimate of the Congressional Budget Office).
Published: (2016)

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act : report (to accompany H.R 2374) (Including cost estimate of the Congressional Budget Office).
Published: (2020)

Food and Drug Amendments of 2022 : report of the Committee on Energy and Commerce (to accompany H.R. 7667).
Published: (2022)

Improving predictability and transparency in DEA and FDA regulation : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, second session, April 7, 2014.
Published: (2015)

Sunscreen Innovation Act : report (to accompany H.R. 4250) (including cost estimate of the Congressional Budget Office).
Published: (2014)

Guidebook for drug regulatory submissions /
by: Weinberg, Sandy, 1950-
Published: (2009)

Amending the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs : report (to accompany H.R. 1407) (including cost estimate of the Congressional Budget Office).
Published: (2013)

Purple Book Continuity Act of 2019 : report (to accompany H.R. 1520) (including cost estimate of the Congressional Budget Office).
Published: (2019)

Reducing Unused Medications Act of 2016 : report (to accompany H.R. 4599).
Published: (2016)

Guidance for industry : major, minor, and telephone amendments to abbreviated new drug applications.
Published: (2001)

Guidance for industry : variations in drug products that may be included in a single ANDA.
Published: (1998)

Guidance for industry : changes to an approved NDA or ANDA, questions and answers.
Published: (2001)

Guidance for industry : changes to an approved NDA or ANDA, specifications, use of enforcement discretion for compendial changes.
Published: (2004)

Guidance for industry : changes to an approved NDA or ANDA.
Published: (2004)

Improving Treatment for Pregnant and Postpartum Women Act of 2016 : report (to accompany H.R. 3691) (including cost estimate of the Congressional Budget Office).
Published: (2016)

Guidance for industry : Q3A impurities in new drug substances.
Published: (2008)

Easy Medication Access and Treatment for Opioid Addiction Act : report (to accompany H.R. 2281).
Published: (2020)

New drug approval : FDA needs to enhance its oversight of drugs approved on the basis of surrogate endpoints : report to the Ranking Member, Committee on Finance, U.S. Senate.
Published: (2009)

Medical writing in drug development : a practical guide for pharmaceutical research /
by: Bonk, Robert J.
Published: (1998)

The pharmaceutical regulatory process /
Published: (2005)

Guidance for industry for the submission documentation for sterilization process validation in applications for human and veterinary drug products.
Published: (1994)

Guidance for industry : referencing discontinued labeling for listed drugs in abbreviated new drug applications.
Published: (2000)

Guidance for industry : NDA's : impurities in drug substances.
Published: (2000)

Guidance for industry : accelerated approval products, submission of promotional materials.
Published: (1999)

Guidance for FDA reviews and sponsors : content and review of chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs).
Published: (2008)

Guideline for submitting supporting documentation in drug applications for the manufacture of drug substances.
Published: (1987)

Dangerous Synthetic Drug Control Act of 2016 : report (to accompany H.R. 3537).
Published: (2016)

Drug-Free Communities Pandemic Relief Act : report (to accompany H.R. 654).
Published: (2021)

State Opioid Response Grant Authorization Act of 2021 : report (to accompany H.R. 2379).
Published: (2021)

Ensuring Patient Access and Effective Drug Enforcement Act of 2015 : report (to accompany H.R. 471) (including cost estimate of the Congressional Budget Office).
Published: (2015)

Ensuring Patient Access and Effective Drug Enforcement Act of 2014 : report (to accompany H.R. 4709) (including cost estimate of the Congressional Budget Office).
Published: (2014)

Methamphetamine Education, Treatment, and Hope Act of 2010 : report (to accompany H.R. 2818) (including cost estimate of the Congressional Budget Office).
Published: (2010)

New drug development : science, business, regulatory, and intellectual property issues cited as hampering drug development efforts : report to congressional requesters.
Published: (2006)

Guidance for industry : qualifying for pediatric exclusivity under section 505A of the Federal Food, Drug, and Cosmetic Act.
Published: (1999)

Guidance for industry : M4, organization of the CTD.
Published: (2001)

Guidance for industry : submission of documentation in applications for parametric release of human and veterinary drug products terminally sterilized by moist heat processes.
Published: (2010)

Opioid Prescription Verification Act of 2021 : report (to accompany H.R. 2355) (including cost estimate of the Congressional Budget Office).
Published: (2021)

CDER ... report to the nation : improving public health through human drugs /
Published: (1998)